NovaBay Pharmaceuticals Inc
$1.4
▲
22.64%
2026-04-21 08:21:00
novabay.com
ASE: NBY
Explore NovaBay Pharmaceuticals Inc stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$51.92 M
Current Price
$1.4
52W High / Low
$99.75 / $1.11
Stock P/E
—
Book Value
$-0.92
Dividend Yield
0%
ROCE
-96.1%
ROE
190.01%
Face Value
—
EPS
$-28.5
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
2
Beta
0.16
Debt / Equity
-0.03
Current Ratio
7.6
Quick Ratio
7.6
Forward P/E
-2.38
Price / Sales
—
Enterprise Value
$45.09 M
EV / EBITDA
-5.95
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Ligand Pharmaceuticals Incorporated | $231.78 | 36.85 | $4.59 B | — | 3.1% | 13.47% | $238.31 / $98.89 | $51.44 |
| 2. | Apellis Pharmaceuticals, Inc. | $40.94 | 233.76 | $5.23 B | — | 7.37% | 7.48% | $40.95 / $16.1 | $2.92 |
| 3. | PTC Therapeutics, Inc. | $72.32 | 8.72 | $5.95 B | — | 44.37% | -104.75% | $87.5 / $35.95 | $-2.52 |
| 4. | OnKure Therapeutics, Inc. | $4.99 | — | $68.37 M | — | -112.02% | -74.39% | $5.06 / $1.7 | $4.11 |
| 5. | Ultragenyx Pharmaceutical Inc. | $25.06 | — | $2.39 B | — | -46.6% | -6.08% | $42.37 / $18.29 | $-0.83 |
| 6. | Silo Pharma, Inc. | $0.67 | — | $8.38 M | — | -61.55% | -74.57% | $1.19 / $0.22 | $0.47 |
| 7. | Alpha Tau Medical Ltd. | $8.11 | — | $706.72 M | — | -44.45% | -61% | $8.6 / $2.5 | $0.88 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | -0.52 M | 0.52 M | 0 M | 0 M | 2.31 M | — |
| Operating Profit | -1.82 M | -1.17 M | -1.89 M | -2.7 M | -1.29 M | — |
| Net Profit | -26.6 M | -1.29 M | -1.92 M | 7.67 M | -1.21 M | — |
| EPS in Rs | -1 | -0.05 | -0.07 | 0.29 | -0.05 | -9.6 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 10.46 M | 14.4 M |
| Operating Profit | -7.58 M | -7.38 M | -4.1 M | -7.68 M |
| Net Profit | -22.14 M | -7.22 M | -9.64 M | -10.61 M |
| EPS in Rs | -0.83 | -0.27 | -0.36 | -0.4 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 9.04 M | 3.42 M | 9.03 M | 16.4 M |
| Total Liabilities | 32.21 M | 3.55 M | 5.72 M | 5.84 M |
| Equity | -23.18 M | -0.13 M | 3.31 M | 10.55 M |
| Current Assets | 8.68 M | 1.94 M | 7.15 M | 11.33 M |
| Current Liabilities | 1.14 M | 2.84 M | 4.28 M | 4.26 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -8.43 M | -7.5 M | -4.26 M | -6.65 M |
| Investing CF | — | 1.06 M | -0.02 M | -0.11 M |
| Financing CF | 4.62 M | 1.5 M | 1.91 M | 4.63 M |
| Free CF | -8.43 M | -7.5 M | -4.28 M | -6.77 M |
| Capex | — | -0.01 M | -0.02 M | -0.11 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | -27.42% | — | — |
| Earnings Growth % | 25.07% | 9.13% | — | — |
| Profit Margin % | — | -92.2% | -73.65% | — |
| Operating Margin % | — | -39.23% | -53.32% | — |
| Gross Margin % | — | 58.19% | 54.02% | — |
| EBITDA Margin % | — | -39.17% | -49.97% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2025-09-30 | $4 |
Stock Splits
| Date | Split |
|---|---|
| 2026-02-23 | 1:0.2 |
| 2024-05-31 | 1:0.0285714 |
| 2022-11-16 | 1:0.0285714 |